Miami, Florida – 13Oct, 2014 – (Tech Sonian)Lion Biotechnologies Inc (OTCMKTS:LBIO)develops T-cells and engineered T-cells for the treatment of various cancers. The company’s lead product candidate includes a ready-to-infuse autologous T-cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with stage IV metastatic melanoma.
Lion Biotechnologies Inc (OTCMKTS:LBIO) opened the session at $6.50, trading in a range of $5.75 – $6.50, and was at $6.00. The stock showed a negative performance of -7.69% in the recent trading session. The stock was trading on a volume of 14,835.00 shares and the average volume of the stock remained 53,957.00 shares.
To receive alerts before the crowd, text the word “CADDY” to “33733″
NuvilexInc (OTCMKTS:NVLX)publicized that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its Cell-in-a-Box(R) treatment for pancreatic cancer. If granted, Orphan Drug Designation in the United States will provide Nuvilex special development and commercial assistance from the FDA, including a 7 year period of marketing exclusivity.
NuvilexInc (OTCMKTS:NVLX), at recent check, traded 527,492.00 shares in the recent trading session and the average volume of the stock remained 1.75 million shares. The 52 week range of the stock remained $0.02 – $0.62. The stock showed a positive movement of 4.59% and was recently trading at $0.193. The market capitalization of the stock remained 137.39 million.
Deutsche Telekom AG (ADR) (OTCMKTS:DTEGY)delivers integrated telecommunication services worldwide. The company maneuvers through four segments: Germany, United States, Europe, and Systems Solutions. It offers fixed-network services, such as voice and data communication services based on fixed-network and broadband technology; and sells terminal equipment and other hardware, as well as services to resellers.